We advised Venrock Healthcare Capital Partners

Davis Polk is advising Venrock Healthcare Capital Partners in connection with its lead investment in the $220 million Series D preferred equity financing of CellCentric Limited.

CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Founded in Cambridge, United Kingdom, the company operates as a transatlantic business with offices in Boston. Venrock is a healthcare-focused, late-stage venture capital fund family that invests primarily in publicly held and late-stage private companies within the healthcare and life sciences industries, with a strong emphasis on small-cap public companies and biotechnology. Venrock focuses on companies developing and commercializing innovative products and technologies.

The Davis Polk corporate team included partners Jared Fine and Yasin Keshvargar, counsel William Tong and associate Laurie Mathias. Members of the Davis Polk team are based in the New York and London offices

Copy link to share post